Qualigen Therapeutics Inc (QLGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qualigen Therapeutics Inc (QLGN) has a cash flow conversion efficiency ratio of -0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.14 Million) by net assets ($38.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Qualigen Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Qualigen Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Qualigen Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Qualigen Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qualigen Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kia Lim Bhd
KLSE:6211
|
0.024x |
|
Lenox Pasifik Investama Tbk PT
JK:LPPS
|
0.000x |
|
ACG Acquisition Co. Ltd.
LSE:ACG
|
0.494x |
|
Bio-Gene Technology Ltd
AU:BGT
|
-0.811x |
|
Mustang Bio Inc
NASDAQ:MBIO
|
-0.117x |
|
Baillie Gifford Shin Nippon PLC
LSE:BGS
|
0.006x |
|
Nala Digital Commerce Ltd
TA:SEFA
|
0.343x |
|
FATHOM NICKEL INC.
F:6Q5
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Qualigen Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Qualigen Therapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Qualigen Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.68 Million | $-6.33 Million | -2.362x | -148.22% |
| 2023-12-31 | $-2.10 Million | $-10.30 Million | 4.898x | +424.16% |
| 2022-12-31 | $8.77 Million | $-13.25 Million | -1.511x | -69.93% |
| 2021-12-31 | $16.56 Million | $-14.73 Million | -0.889x | -66.77% |
| 2020-12-31 | $18.29 Million | $-9.76 Million | -0.533x | -1123.08% |
| 2019-12-31 | $1.10 Million | $57.33K | 0.052x | +103.67% |
| 2018-12-31 | $9.39 Million | $-13.33 Million | -1.420x | -286.43% |
| 2017-12-31 | $20.13 Million | $-7.40 Million | -0.368x | +90.08% |
| 2016-12-31 | $4.10 Million | $-15.21 Million | -3.707x | -851.36% |
| 2015-12-31 | $14.68 Million | $-5.72 Million | -0.390x | +42.48% |
| 2014-12-31 | $1.71 Million | $-1.16 Million | -0.677x | -112.12% |
| 2013-12-31 | $-350.25K | $-1.96 Million | 5.587x | +271.69% |
| 2012-12-31 | $946.03K | $-3.08 Million | -3.254x | -- |
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS tha… Read more